Report Overview

The China liver disease therapeutics market size stood at around USD 9.08 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of xx% during the forecast period.

A total of 13.54 million deaths were attributable to liver diseases over the period between 1987 and 2016, resulting in an average of 36.15 deaths per 100 000 population per year. The risk of PLC (Primary liver cancer) mortality increased by 32.69% over the period after controlling for the effects of age and birth cohort. By contrast, the risk of CLD (Chronic liver disease) mortality decreased by 56.64% over the same period. The risk of VH (Viral hepatitis) mortality decreased first, followed by a resurgence after the period of 20022006. Similar mortality risk trends by age (increasing) and birth cohort (decreasing) were observed for PLC and CLD. China has achieved great success in reducing the mortality of VH and CLD. However, significant challenges lie ahead in the efforts to prevent and control PLC and the resurgence of VH.



Market Drivers

The growth of the Liver disease therapeutics market in china is majorly driven by factors such as unorganized lifestyles, rising public awareness, increasing alcohol consumption, Unmet needs for the treatment of liver cancer, and a Growing obese and diabetic population. The increasing prevalence of liver disease is also a major factor that is driving the growth of this market like approximately 7% of the population in China is affected by hepatitis among which many are at risk of developing chronic liver cancer and cirrhosis. The annual alcohol consumption per capita in China has climbed from 3.3 L in 1987 to 5.74 L in 2016.

The key restraint of this market are the side effects associated with the products, Competition from herbal medicines, and high costs associated with the liver disease treatment market.